Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026
Company Deals

Iktos and Servier Forge EUR 1 Billion+ AI Drug Discovery Collaboration

Fineline Cube Jan 14, 2026
Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Fineline Cube Jan 14, 2026
Company Drug

Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors

Fineline Cube Jan 14, 2026
Company Drug

HutchMed Completes NDA Submission to US FDA for Frquintinib in Metastatic CRC

Fineline Cube Mar 31, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of a rolling...

Company Deals

Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as ‘APLM’

Fineline Cube Mar 31, 2023

Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the...

Company Drug

Huadong Medicine Wins NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes

Fineline Cube Mar 31, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it...

Company Deals

Ablaze Pharma Charts Path for GPC3-Targeted Polypeptide with RayzeBio Partnership

Fineline Cube Mar 31, 2023

Ablaze Pharma, a Chinese biopharmaceutical company, has announced its development plan for a GPC3-targeted polypeptide...

Company Drug

Fosun Pharmaceutical Gets NMPA Approval for FCN-159 Phase II Study in LCH

Fineline Cube Mar 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...

Company Drug

Shanghai Fosun Pharma Commences Phase III Trial for HER2-Targeted FS-1502

Fineline Cube Mar 31, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent Chinese pharmaceutical company,...

Company Deals

Kangtai Bio Partners with AstraZeneca and Combiphar to Expand Vaccine Collaboration

Fineline Cube Mar 31, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese vaccine manufacturer, has entered...

Company Drug

CStone Pharmaceuticals’ Sugemalimab Study Published in JCO for R/R ENKTL Treatment

Fineline Cube Mar 31, 2023

CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, announced that the Journal of Clinical Oncology...

Medical Device

IceCure Medical Gains NMPA Approval for Cryoablation Technology in China

Fineline Cube Mar 31, 2023

Israel-based IceCure Medical (NASDAQ: ICCM) has announced that it has obtained regulatory approval from China’s...

Company Deals

SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal

Fineline Cube Mar 31, 2023

China-based SciNeuro Pharmaceuticals and Germany’s Secarna Pharmaceuticals GmbH & Co. KG have announced a research...

Company Deals

Beijing’s QL Bio Secures Tens of Millions in Funding for Proteomics Platform Upgrade

Fineline Cube Mar 30, 2023

QL Bio, a Beijing-based proteomics testing company, has reportedly secured tens of millions of renminbi...

Company Drug

ImmVira’s MVR-C5252 Receives NMPA Approval for Glioma Treatment Development

Fineline Cube Mar 30, 2023

China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for...

Policy / Regulatory

Round 8 VBP Tender Results Announced with RMB 21.6 Billion Market

Fineline Cube Mar 30, 2023

The National Allied Procurement Office has issued an initial notification upon the completion of Round...

Company

Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials

Fineline Cube Mar 30, 2023

Global biotechnology company Harbour BioMed (HKG: 2142), with operations in the United States, the Netherlands,...

Company Drug

Janssen to Halt RSV Adult Vaccine Development, Impacting Phase III Trial

Fineline Cube Mar 30, 2023

Johnson & Johnson (J&J; NYSE: JNJ) subsidiary, Janssen, has announced its decision to terminate its...

Company

Luye Pharma Group Reports 15% Revenue Growth in 2022 Financial Results

Fineline Cube Mar 30, 2023

China-based Luye Pharma Group (HKG: 2186) has released its 2022 financial report, recording a total...

Company Drug

Pfizer’s Ritlecitinib Heads for Priority Review in China for Vitiligo Treatment

Fineline Cube Mar 30, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Pfizer’s (NYSE: PFE) ritlecitinib,...

Company Deals

Boston Scientific Partners with Scivita Medtech for Disposable Electronic Cholangioscope

Fineline Cube Mar 30, 2023

Boston Scientific Corporation (NYSE: BSX), a leading figure in the medical device industry, has announced...

Company Drug

Transcenta’s Osemitamab Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Mar 30, 2023

China-based biotechnology company Transcenta Holdings Ltd (HKG: 6628) has announced that its drug TST001 (osemitamab),...

Company Deals

CNBG Partners with China CDC to Strengthen Disease Prevention and Public Health

Fineline Cube Mar 30, 2023

China National Biotec Group Company Limited (CNBG) has announced a significant long-term partnership with the...

Posts pagination

1 … 486 487 488 … 609

Recent updates

  • ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination
  • Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors
  • U‑Yin Pharma’s EHT102 Gene Therapy Scores IND Approval Under NMPA’s 30‑Day Review for DFNB9 Hearing Loss
  • Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital
  • Haichang Biotech’s HC016 Receives FDA Orphan Drug Designation for Osteosarcoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Company Drug

Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors

Company Drug

U‑Yin Pharma’s EHT102 Gene Therapy Scores IND Approval Under NMPA’s 30‑Day Review for DFNB9 Hearing Loss

Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.